Danish drug manufacturer Novo Nordisk's diabetes subsegment of glucagon-like peptide 1 (GLP-1) products generated nearly 150 billion kroner in 2024. The company's total insulin-related sales stood at some 55 billion kroner, of which fast-acting insulins formed the largest single share.
Novo Nordisk's diabetes care sales by subsegment in 2024
(in million DKK)
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Novo Nordisk. (February 5, 2025). Novo Nordisk's diabetes care sales by subsegment in 2024 (in million DKK) [Graph]. In Statista. Retrieved June 07, 2025, from https://www.statista.com/statistics/1202417/novo-nordisk-sales-by-diabetes-subsegments/
Novo Nordisk. "Novo Nordisk's diabetes care sales by subsegment in 2024 (in million DKK)." Chart. February 5, 2025. Statista. Accessed June 07, 2025. https://www.statista.com/statistics/1202417/novo-nordisk-sales-by-diabetes-subsegments/
Novo Nordisk. (2025). Novo Nordisk's diabetes care sales by subsegment in 2024 (in million DKK). Statista. Statista Inc.. Accessed: June 07, 2025. https://www.statista.com/statistics/1202417/novo-nordisk-sales-by-diabetes-subsegments/
Novo Nordisk. "Novo Nordisk's Diabetes Care Sales by Subsegment in 2024 (in Million Dkk)." Statista, Statista Inc., 5 Feb 2025, https://www.statista.com/statistics/1202417/novo-nordisk-sales-by-diabetes-subsegments/
Novo Nordisk, Novo Nordisk's diabetes care sales by subsegment in 2024 (in million DKK) Statista, https://www.statista.com/statistics/1202417/novo-nordisk-sales-by-diabetes-subsegments/ (last visited June 07, 2025)
Novo Nordisk's diabetes care sales by subsegment in 2024 (in million DKK) [Graph], Novo Nordisk, February 5, 2025. [Online]. Available: https://www.statista.com/statistics/1202417/novo-nordisk-sales-by-diabetes-subsegments/